- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Clarence Moore Discusses Patient Accessibility to Beta Thalassemia Treatments
Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses whether treatment methods for beta thalassemia are accessible to patients.
Transcript:
How accessible are treatments for beta thalassemia? What is the process for patients and where can they go for support?
It all depends on what region of the country individuals are from. Historically, the treatments were specifically just blood transfusion. So, you could potentially get blood transfusions and various locations. But the more transfusions an individual has had, the more types of antigens they will be exposed to.
So, being able to receive blood that is matched specifically to them I think is very important. I'm looking at some of the treatments. I'm definitely looking at various formularies, [like] chelation therapy, to determine which products may be approved by one's insurance or which one is going to be recommended based on the recommendation of the physician or the medical team. I think that is also something of importance.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
